The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Parfenov V.A.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Moskva

Zhivolupov S.A.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Nikulina K.V.

OOO «NPF “Materia Medica Holding”», Moscow, Russia

Poverennova I.E.

Kafedra nevrologii i neĭrokhirurgii Samarskogo gosudarstvennogo meditsinskogo universiteta

Lapatuhin V.G.

Penza Institute of Improvement of Doctors, Penza, Russia

Zhestikova M.G.

Novokuznetsk State Institut of Improvement of Doctors, Novokuznetsk

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Glazunov A.B.

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT

Authors:

Parfenov V.A., Zhivolupov S.A., Nikulina K.V., Poverennova I.E., Lapatuhin V.G., Zhestikova M.G., Zhukova N.G., Glazunov A.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6): 15‑23

DOI: 10.17116/jnevro20181186115

Views: 804

Downloaded: 19

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Parfenov VA, Zhivolupov SA, Nikulina KV, et al. . Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6):15‑23. (In Russ.)
https://doi.org/10.17116/jnevro20181186115

 
МСФ на ЯМ
Close metadata
Recommended articles:
Neurometabolic therapy of mild cognitive impairment in patients with chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):42-51
Resu­lts of a pilot study of the stru­cture and evaluation of the therapy for chro­nic sleep diso­rders in como­rbid patients with chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):118-126
Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24
Effi­cacy and safety of choline alfo­scerate in the preventive therapy of deme­ntia in elde­rly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99
Meta-analysis of randomized controlled trials of the effe­ctiveness of Prospekta in the treatment of vascular cognitive impairment of varying seve­rity. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):62-69
Significance of immu­nological markers in patients with obstructive sleep apnea and como­rbid pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):47-53
Clinical effi­cacy and safety of Pica­milon in patients with progressive chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):71-80
Immu­nological and neuroanatomic markers of the clinical dyna­mics of MCI and pre-MCI. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):81-91
Cere­brolysin in the preventive therapy of deme­ntia in elde­rly patients with mild cognitive impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):51-59
Effi­cacy of different postural control training in elde­rly people with chro­nic cere­bral ischemia. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):42-48

Objective. To investigate the efficacy of divaza in outpatients with cognitive disorders and chronic brain ischemia (CBI). Material and methods. The non-interventional observational program included the data of 2583 outpatients with CBI from 30 cities (8 federal okrugs of the Russian Federation) who were on outpatient neurological treatment and received divaza in a dose of 2 tablets three times a day from Oct 2016 to Jan 2017. Cognitive functions were evaluated using the MoCA scale before and after 3 months of treatment. Results and conclusion. Cognitive disorders were identified in 90.7% of patients (<26 MoCA scores). After treatment, the mean MoCA score increased from 19.58±5.13 to 23.99±4.21 (p<0.0001), the number of patients with normal cognitive functions rate (≥26 scores) increased from 9.3 to 41.3%, the number of patients with marked cognitive impairment decreased. The drug was well-tolerated by old and very old patients, adverse events were observed rarely (0.6% of cases). The majority of doctors (88.4%) noticed the effect of divaza as significant improvement or improvement, and 89.6% of patients valued the effect to be excellent or good. The use of divaza, the drug with endothelioprotective and nootropic effects, is pathogenetically justified and promising in patients with cognitive disorders of vascular etiology.

Keywords:

mild cognitive impairment
hypertension-associated microangiopathy
MoCA test
observational program
divaza

Authors:

Parfenov V.A.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Moskva

Zhivolupov S.A.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Nikulina K.V.

OOO «NPF “Materia Medica Holding”», Moscow, Russia

Poverennova I.E.

Kafedra nevrologii i neĭrokhirurgii Samarskogo gosudarstvennogo meditsinskogo universiteta

Lapatuhin V.G.

Penza Institute of Improvement of Doctors, Penza, Russia

Zhestikova M.G.

Novokuznetsk State Institut of Improvement of Doctors, Novokuznetsk

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Glazunov A.B.

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

List of references:

  1. Petersen R, Lopez O, Armstrong M, Getchius T, Ganguli M, Gloss D, Gronseth G, Marson D, Pringsheim T, Day G, Sager M, Stevens J, Rae-Grant A. Practice guideline update summary: Mild cognitive impairment. Neurology. 2017;90(3):126-135. https://doi.org/10.1212/wnl.0000000000004826
  2. Ganguli M. Epidemiology of Dementia. Principles and Practice of Geriatric Psychiatry. 2010;3:207-212. https://doi.org/10.1002/9780470669600.ch38
  3. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-2713. https://doi.org/10.1161/STR.0b013e3182299496
  4. Sachdev P, Kalaria R, O’Brien J, Skoog I, Alladi S, Black S, Blacker D, Blazer D, Chen C, Chui H, Ganguli M, Jellinger K, Jeste D, Pasquier F, Paulsen J, Prins N, Rockwood K, Roman G, Scheltens P. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. https://doi.org/10.1097/wad.0000000000000034
  5. Parfenov VA. Distsirkulyatornaya entsefalopatiya i sosudistye kognitivnye rasstroistva. M: IMA-PRESS; 2017. (In Russ.)
  6. De Silva M, Faraci F. Microvascular Dysfunction and Cognitive Impairment. Cell Mol Neurobiol. 2016; 36(2):241-58. https://doi.org/10.1007/s10571-015-0308-1
  7. Faraci FM. Protecting against vascular disease in brain. Amer J Physiol. 2011;300:1566-1582. https://doi.org/10.1152/ajpheart.01310.2010
  8. Zakharov VV, Yakhno NN. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste. Metodicheskoe posobie dlya vrachei. M. 2005. (In Russ.)
  9. Snyder H, Corriveau R, Craft S, Faber J, Greenberg S, Knopman D, Lamb B, Montine T, Nedergaard M, Schaffer C, Schneider J, Wellington C, Wilcock D, Zipfel G, Zlokovic B, Bain L, Bosetti F, Galis Z, Koroshetz W, Carrillo M Vascular Contributions to Cognitive Impairment and Dementia Including Alzheimer’s Disease. Alzheimers Dement. 2015;11(6):710-717. https://doi.org/10.1016/j.jalz.2014.10.008
  10. Fedin AI, Starykh EP, Putilina MV, Starykh EV, Mironova OP, Badalyan KR. Endothelial dysfunction in patients with chronic cerebral ischemia and the possibilities of its pharmacological correction. Lechashchii vrach. 2015;5:15-21. (In Russ.)
  11. Suarez EC, Sundy JS, Erkanli A. Depressogenic vulnerability and gender-specific patterns of neuro-immune dysregulation: What the ratio of cortisol to C-reactive protein can tell us about loss of normal regulatory control. Brain, Behavior, and Immunity Elsevier BV. 2015;44:137-147. https://doi.org/10.1016/j.bbi.2014.09.008
  12. Kamchatnov PR, Vorob’eva OV, Rachin AP. Korrektsiya emotsional’nykh i kognitivnykh narushenii u patsientov s khronicheskoi ishemiei golovnogo mozga. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(4):52-57. (In Russ.)
  13. Fateeva VV, Vorob’eva OV, Glazunov AB. Endotelial’naya disfunktsiya — farmakologicheskaya mishen’ v terapii affektivnykh rasstroistv u patsientov s serdechno-sosudistymi zabolevaniyami. Consilium Medicum. 2017;19(2):84-88. (In Russ.)
  14. Fateeva VV, Vorob’eva OV. Markery endotelial’noi disfunktsii pri khronicheskoi ishemii mozga. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(4):106-110. (In Russ.) https://doi.org/10.17116/jnevro201711741107-111
  15. Parfenov VA, Kamchatnov PR, Vorob’eva OV, Gustov AV, Glushkov KS, Doronina OB. Rezul’taty mnogotsentrovogo issledovaniya effektivnosti i bezopasnosti primeneniya preparata divaza pri astenicheskikh i legkikh ili umerennykh kognitivnykh rasstroistvakh v pozhilom i starcheskom vozraste. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(9):43-50. (In Russ.) https://doi.org/10.17116/jnevro20171179143-50
  16. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
  17. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64:191-199. https://doi.org/10.1093/biomet/64.2.191
  18. Khat’kova SE, Akulova MA, Orlova OR, Orlova AS. Sovremennye podkhody k reabilitatsii bol’nykh posle insul’ta. Nervnye bolezni. 2016;3:27-33. (In Russ.)
  19. Antipenko EA, Gustov AV. Cronic brain ischemia. Current state of the problem. Meditsinskii sovet. 2016;19:38-43. (In Russ.) https://doi.org/10.21518/2079-701x-2016-19-38-43
  20. Zakharov VV. All-Russia epidemiological and therapeutic investigation concerning cognitive impairment in the elderly («Prometheus»). Nevrologicheskii zhurnal. 2006;11(2):27-32. (In Russ.)
  21. Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol. 2007;113(4):349-388. https://doi.org/10.1007/s00401-006-0185-2
  22. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-2204. https://doi.org/10.1212/01.wnl.0000271090.28148.24
  23. Benedictus MR, van Harten AC, Leeuwis AE, Koene T, Scheltens P, Barkhof F, Prins N, van der Flier W. White matter hyperintensities relate to clinical progression in subjective cognitive decline. Stroke. 2015;46:2661-2664. https://doi.org/10.1161/strokeaha.115.009475
  24. World Health Organization. Dementia: A Public Health Priority. Geneva: World Health Organization; 2012. Accessed March 21, 2018. http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf
  25. Reiman EM, Langbaum JBS, Tariot PN. Alzheimer’s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med. 2010;4:3-14. https://doi.org/10.2217/bmm.09.91
  26. Damulin IV. Bolezn’ Al’tsgeimera i sosudistaya dementsiya. Pod red. Yakhno N.N. M. 2002. (In Russ.)
  27. Yakhno NN, Zakharov VV, Lokshina AB, Koberskaya NN, Mkhitaryan EA. Dementsii. Rukovodstvo dlya vrachei. M.: MEDpress-inform; 2011. (In Russ.)
  28. Starchina YuA. Cognitive impairment without dementia: A current view of the problem. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2017;2:71-76. (In Russ.) https://doi.org/10.14412/2074-2711-2017-2-71-76
  29. Parfenov VA, Starchina YuA, Yakhno NN. Eprosartan (teveten) administration for the prevention of recurrent stroke and cognitive impairment. Nevrologicheskii zhurnal. 2007;1:46-51. (In Russ.)
  30. Parfenov VA, Khasanova DR. Ishemicheskii insul’t. M.: MIA; 2012. (In Russ.)
  31. Tanaeva KK, Dugina YuL, Kachaeva EV, Epshtein OI. Prospects of the novel combined drug divaza in the pathogenetic treatment of chronic cerebral Ischemia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(9):94-98. (In Russ.)
  32. Zhavbert ES, Gur’yanova NN, Surkova EI, Dugina YuL, Kachaeva EV, Epshtein OI. Issledovanie vliyaniya Divazy na protsessy perekisnogo okisleniya lipidov. XXI Rossiiskii natsional’nyi kongress «Chelovek i lekarstvo». M. 2014. (In Russ.)
  33. Kardash EV, Gorbunov EA, Tarasov AV, Yakovleva NN, Tarasov SA. Vliyanie divazy na sigma retseptory, reguliruyushchie osnovnye neiromediatornye sistemy. XXIII Rossiiskii natsional’nyi kongress «Chelovek i lekarstvo». M. 2014. (In Russ.)
  34. Ganina KK, Dugina YuL, Zhavbert ES, Ertuzun IA, Epshtein OI, Mukhin VN, Abdurasulova IN. Antiamnesic effects divaza and its component model β-amyloid amnesia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116(9):69-74. (In Russ.) https://doi.org/10.17116/jnevro20161169169-74
  35. Neimark AI, Aliev RT, Muzalevskaya NI, Krainichenko SV, Vorob’eva EN, Tarasova TS. Treatment of erectile dysfunction in patients with essential hypertension and ischemic heart disease. Terapevticheskii arkhiv. 2008; 80(4):60-63. (In Russ.)
  36. Belous AS, Pokrovskii MV, Kochkarov VI, Pokrovskaya TG, Artyushkova EB, Pashin EN, Brusnik MV, Chulyukova TN, Klyavs YuP, Korneev MM, Zelenkova TI, Malykhin VA, Zaloznykh YaI. Endothelio- and cardioprotective effects of the admixture of homeopathic delutions afinn cleared polyclonal rabbit antibodies to endothelial nitrogen oxidi sintase (enos) C12, C30, C200 in experimental modelling L-NAME-induced endothelial dysfunction. Kubanskii nauchnyi meditsinskii vestnik. 2007;1-2(94-95):23-26. (In Russ.)
  37. Arustamova AA. Protivoishemicheskoe i endotelioprotektivnoe deistvie potentsirovannykh antitel k endotelial’nomu faktoru rosta sosudov: Dis... kand. biol. nauk. Belgorod. 2011. (In Russ.)
  38. Belova AN, Shakurova DN, Gayazova EV. Possibilities of using naftidrofuryl in the therapy of cerebrovascular diseases: Literature review and the authors’ observations. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2015;4:110-115. (In Russ.) https://doi.org/10.14412/2074-2711-2015-4-110-115
  39. Dolgova IN, Karpov SM, Minaev AB, Vyshlova IA, Chigrina NV. The use of mexiprim in patients with chronic brain ischemia. Kubanskii nauchnyi meditsinskii vestnik. 2016;1(156):35-39. (In Russ.)
  40. Shchukin IA, Lebedeva AV, Fidler MS. Chronic cerebrovascular disease: diagnosis and treatment questions. Meditsinskii sovet. 2016;8:68-75. (In Russ.)
  41. Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017;48(5):1262-1270. (Accessed March 21, 2018). https://clinicaltrials.gov/ct2/show/NCT01582854 https://doi.org/10.1161/STROKEAHA.116.014321
  42. Julayanont P, Phillips N, Chertkow H, Nasreddine ZS. Montreal Cognitive Assessment (MoCA): Concept and Clinical Review. In: Larner A. (eds). Cognitive Screening Instruments. London: Springer; 2013. https://doi.org/10.1007/978-1-4471-2452-8_6
  43. Freitas S, Simões M, Marôco J, Alves L, Santana I. Construct Validity of the Montreal Cognitive Assessment (MoCA). Journal of the International Neuropsychological Society. 2012;18(2):242-250. https://doi.org/10.1017/S1355617711001573
  44. Chang YT, Chiung-Chih C, Hung-Sheng L, Che-Wei H, Wen-Neng C, Chun-Chung L, Chen-Chang L, Yu-TL, Chang-Hung C, Nai-Ching C. Montreal Cognitive Assessment in Assessing Clinical Severity and White Matter Hyperintensity in Alzheimer’s Disease with Normal Control Comparison. Acta Neurol Taiwan. 2012;21:64-73. https://doi.org/10.5772/24298
  45. Tanashyan MM, Lagoda OV, Antonova KV, Raskurazhev AA, Chatskaya AV. Kognitivnaya disfunktsiya u patsientov s tserebrovaskulyarnymi zabolevaniyami i narusheniyami uglevodnogo obmena. Klinicheskaya farmakologiya i terapiya. 2017;26(5):25-30. (In Russ.)
  46. Gavrilova SI. Farmakoterapiya bolezni Al’tsgeimera. M.: Pul’s; 2003. (In Russ.)
  47. Knopman DS. Current treatment of mild cognitive impairment and Alzheimer’s disease. Cur Neurol Nerosci Rep. 2006;6(5):365-371. https://doi.org/10.1007/s11910-996-0016-9
  48. Kurshner HS. Mild cognitive impairment: to treat or not to treat? Cur Neurol Neurosci Rep. 2005;5(6):455-457. https://doi.org/10.1007/s11910-005-0033-0

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.